Background: Abietic acid (AA) is one of the terpenoids, which are multifunctional natural compounds. It has been reported that AA possesses favorable therapeutic effects on inflammation and obesity. Method: In the present study, we determined the inhibitory effect of AA on the proliferation and growth of non-small-cell lung cancer (NSCLC) cell lines for the first time. Then, flow cytometry and Western blot analysis were applied to determine the cell apoptosis and cell cycle. Finally, surface plasmon resonance, molecular docking and molecular dynamics (MD) simulation were performed to explore the underlying molecular mechanisms. Results: In vitro experiments indicated that AA displays significant anti-proliferative, cell cycle arresting and pro-apoptotic activities. Mechanistically, AA abrogated tumor necrosis factor-α induced phosphorylation of IκB kinase (IKKα/β) (Ser176/180) and IkBα (Ser32), and inhibited the nuclear translocation of nuclear factor-κB. Moreover, we found that the activities of AA against NSCLC cells were mediated by its IKKβ inhibition. Molecular docking and MD simulations demonstrated that the mechanism of action between AA and IKKβ was through hydrophobic interactions. Conclusion: Our data indicate that AA could be a promising lead compound for the discovery of novel IKKβ inhibitors and potential agents for the treatment of NSCLC.
Introduction
Lung cancer is the most commonly diagnosed cancer (11.6% of the total cases) and the leading cause of cancer death (18.4% of the total cancer deaths) worldwide. 1 Non-small-cell lung cancer (NSCLC) accounts for >85% of all lung cancer cases, for which the predicted 5-year survival rate is extremely poor (15.9%).
based doublet chemotherapy, 6 however there is still an urgent need to identify more effective drugs with lower toxicity for the treatment of NSCLC. Natural products (NPs) have proven a reliable and consistent source for medicinal chemistry research and drug discovery in recent decades. 7 NPs display a broadspectrum of biological effects, including well-studied properties such as anti-inflammatory, anti-microbial, and especially anti-tumor activities. Approximately 60% of clinically approved antitumor drugs have reportedly originated from NPs. 8 Paclitaxel, vinblastine and doxorubicin, for example, are the most well-known chemotherapies in clinical use at present. 9 Compared to alkylating antineoplastic agents or antimetabolite antitumor agents, NPderived antitumor drugs offer a remarkable advantage of having lower toxicity to normal tissues. On the other hand, NPs are often perceived as chemically complex, differing from synthetic drug-like molecules in many respects. Fragment-like NPs with innovative scaffolds have great promise for their use as starting points in chemical biology and medicinal chemistry fields.
In recent years, it is well recognized that IκB kinase (IKK)/nuclear factor-κB (NF-κB) signal pathway plays a crucial role in the pathogenesis of a number of human diseases, including asthma, neurodegeneration, inflammation and cancers. In the canonical NF-κB pathway, cell is stimulated by various stimuli such as tumor necrosis factor-α (TNF-α), IL-1 and lipopolysaccharides. Subsequently, these activators trigger IKKβ phosphorylated by TGF-β-activated kinase 1, then the phosphorylation signals were transferred to the inhibitory IκB proteins, leading to their rapid ubiquitination and proteasomemediated degradation, which finally makes NF-κB nuclear translocated and various NF-κB-related tumor-promoting genes transcribed including Bcl-2, Cyclin D1, survivin, and so on. Based on early studies that identified IKKβ as a key tumor promoter via driving the classical NF-κB signaling activation, several potent synthetic inhibitors of IKKβ have developed. However, the reports on the NPderived IKKβ inhibitors are still pretty rare. 10 Abietic acid (AA) is an abietane diterpenoid compound mainly derived from Pimenta racemosa var. grissea, which reportedly possesses anti-allergenic, antiinflammatory, anti-obesity and anti-convulsant activities. [11] [12] [13] [14] In recent studies, researchers found AA and its analogs display novel anti-tumor effects as potential adjuvant therapy agents. [15] [16] [17] Hsieh reported that AA not only effectively suppressed melanoma cancer cell metastasis in both in vitro and in vivo models, it also improved the efficacy of taxol against B16F10 cells.
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Furthermore, Yoshida reported that AA inhibits MRP2-or BCRP-mediated membrane transport and their interaction with substrate. 18 However, beyond these, evaluations of the anti-proliferative activity of AA have been extremely rare, the complete anti-cancer potential of AA has yet to be revealed. In our study, we first screened the killing ability of AA on six NSCLC cell lines. Cell proliferation (MTS assay) and clone formation results suggested AA remarkably inhibited the proliferation and growth of NSCLC cells. Flow cytometry and Western blot analysis data indicated that AA effectively arrested the cell cycle of NSCLC cells at the G0/G1phase and induced apoptosis. Furthermore, mechanistic investigation results revealed AA was a potential IKKβ inhibitor. IKKβ overexpression by specific plasmid was conducted. The phenotype results showed the anti-cancer role of AA was greatly impaired, further indicating the activity of AA is mediated through the IKKβ/NF-κB signaling inhibition. At last, the interaction between IKKβ and AA was simulated through molecular docking and molecular simulations, which demonstrated the hydrophobic interaction may contribute to their binding interaction.
Materials and methods

Cell culture and reagents
The human pulmonary epithelial cells Beas-2B and NSCLC cell lines A549, H460, HCC827, H1650, PC-9 and H1975 were obtained from Shanghai Institute of Biosciences and Cell Resources Center (Chinese Academy of Sciences, Shanghai, China). The cells were routinely cultured in RPMI-1640 or DMEM (Gibco/BRL lifeTechnologies, Eggenstein, Germany) supplemented with 10% fetal bovine serum FBS (Hyclone, Logan, UT, USA), 1% penicillin/streptomycin solution in a humidified atmosphere of 5% CO 2 at 37°C. The primary antibodies used in this study, including p-IKKβ (Ser176/180), IKKβ, p-IκBα (Ser32), IKBα, Bcl-2, cleaved-PARP, Cyclin D1, Cdk-4 and Actin were all purchased from Cell Signaling Technology (Danvers, MA, USA). Goat anti-rabbit IgG-horseradish peroxidase (HRP) secondary antibody was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA); AA was purchased from Solorbio (Beijing, China). and the purity of AA detected by HPLC was over 99% ( Figure S1 ). Human recombinant IKKα and IKKβ protein was purchased from Abcam (Cambridge, UK), and their purities were both >85% assessed by SDS-PAGE (Manufacturer datasheet). The pcDNA-Ikkb-FLAG WT plasmid was purchased from Addgene (MA, USA).
Transfection of plasmid
For plasmid transfections, cells were seeded overnight and plasmids were transfected with X-treme GENE HP DNA Transfection Reagent (Roche Applied Science, Shanghai, China) according to the manufacturer's instructions. Cells were harvested for protein extraction after 48 hrs of transfection. 
Cell viability assay
Cell cycle analysis
Cells (3×10 5 cells/well) were seeded in 6-well plates and allowed to adhere overnight. The next day, the cells were treated with different compounds as indicated for 24 hrs. Then, the cells were trypsinized, washed, and fixed in 75% ice-cold ethanol at 4°C overnight. After centrifugation, the pellets were washed with cold PBS, suspended in 500 μL PBS with 50 mg/mL PI and incubated at 4°C for 30 mins in the dark. Then, cell suspension was subjected to a FACS Calibur instrument (Becton Dickinson FACSCalibor; BD Biosciences).
Western blotting
After treated as indicated for 24 hrs, the cells were washed once by PBS. The cell lysates were quantitated by BCA protein assay kit (Bio-Rad Laboratories, Hercules, CA, USA). Equal amounts of proteins were separated by SDS-PAGE and transferred to PVDF membrane. After being blocked with 5% non-fat dry milk in TBST for 1.5 hrs, membranes were incubated with a 1:1,000 dilution of specific primary antibody overnight at 4°C and the secondary antibody conjugated with HRP (1:5,000; Santa Cruz Biotechnology) for 2 hrs, the immunoreactive bands were visualized with enhanced chemiluminescence (EMD Millipore, Billerica, MA, USA) in Amersham Imager 600 system (GE Healthcare Life Sciences, Shanghai, China).
Surface plasmon resonance (SPR) analysis
SPR experiments were performed on a ProteOn XPR36 Protein Interaction Array system (Bio-Rad Laboratories). Briefly, IKKβ solution in PBST (5 mM, pH 7.4) at a concentration of 1 mg/mL was diluted to 30 μg/mL with sodium acetate buffer (pH 4.5). The chip was activated with EDC/NHS (10 μL/min for 600 s). Then, IKKβ was loaded (5 μL/min for 400 s) and immobilized covalently. Approximately 8,000 RU of IKKβ was immobilized on the chip. Any excess of unbound IKKβ was removed by flowing PBS solution (5 mM, pH 7.4, with 5%, w/v, DMSO). AA was prepared as 20-100 μM solution in PBS solution (5 mM, pH 7.4, with 5%, w/v, DMSO), and injected (10 μL/min for 100 s). Five concentrations were injected simultaneously at a flow rate of 30 μM/min for 120 s of association phase, followed with 120 s of dissociation phase at 25°C. The final graph was obtained by subtracting blank sensorgrams from the duplex or quadruplex sensorgrams. Data were analyzed by ProteOn manager software.
Construction of the initial structure of IKKβ/AA complex
The crystal structure of IKKβ was retrieved from the Protein Data Bank (PDB) database (PDB code: 4KIK).
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The crystal structure of IKKβ was refined by UCSF Chimera program, 20 including removing all water molecules, non-bonded hetero-atoms, and adding missing hydrogen atoms. Then, the binding pose of AA in the allosteric pocket between the kinase domain and ubiquitin-like domain was predicted by the AutoDock program as previous study. 21, 22 The program and AA were processed by AutoDockTools 1.5.6 program. 21 A grid box size of 22.5 Å ×22.5 Å ×22.5 Å dimensions, with a spacing of 0.375 Å between the grid points, was selected and covered the entire allosteric pocket. Lamarckian Genetic Algorithm was applied to conformational sampling with trials of 200 dockings, maximum number of evaluation 25,000,000 and other settings were set as default. The lowest binding energy conformation was used for molecular dynamics (MD) simulation analysis.
Molecular dynamics (MD) simulation
The IKKβ/AA complex provided by molecular docking was used as the initial structure for the MD simulations. The partial atomic charges for AA were evaluated by the restrained electrostatic potential (RESP) method based on HF/6-13G* basis set. Then, the complex was processed by the LEaP module in AmberTools14. The ff14SB force field was assigned to the IKKβ residues, and General Amber Force Field 2 was used to describe the AA. 23, 24 Thereafter, the complex was immersed in a rectangular box of water molecules (TIP3P). Finally, counterions were added to neutralize the modeled system. Before the productive MD simulations, the system was minimized by 8,000 steps of steepest descent followed by 8,000 steps of conjugate gradient to remove the bad contacts in the modeled structure. Then, the system was heated up from 0 to 300 K in 300 ps at a constant force of 6.0 kcal/mol Å −2 to constrain the protein atoms. After heating, 200 ps density procedure at 300 K and 200 ps equilibration in the isothermalisobaric (NPT) ensemble were applied to raise the density and control the temperature of the system. In the end, a 100 ns MD simulation was performed at a constant temperature of 300 K and a constant pressure of 1 atm. Coordinates were recorded every 4 ps and numerical analysis was calculated by CPPTRAJ module in Amber14. 25 A total of 500 snapshots extracted from the last 20 ns MD trajectory were applied for the binding free energy calculations by using molecular mechanics/generalized Born surface area (MM/GBSA) method. 26 
Statistical analysis
The results are presented as the mean ± standard error (SEMs). The statistics were performed using one-way ANOVA in GraphPad Pro (GraphPad, San Diego, CA, USA). P-values <0.05 were considered statistically significant. All the experiments were repeated a minimum of three times. All of the aforementioned experiments were repeated thrice.
Results
AA inhibits NSCLC cell proliferation and colony formation
Firstly, the anti-proliferative effects of AA ( Figure 1A ) against normal human pulmonary epithelial cells (Beas-2B) and six NSCLC cell lines was tested by means of colorimetric MTS assays. As shown in Figure 1B , AA exhibited the most potent inhibitory effect on PC-9 and H1975 cells, with IC 50 values of 14.54 μM and 19.97 μM, respectively. Therefore, these two cell lines were chosen for the next experiments. In addition, the status of EGFR mutations of the NSCLC cell lines is listed in Table 1 . Combined the EGFR mutational status of NSCLC cell lines with the MTS assay results, it indicated that AA exerted the anti-proliferative effects through an EGFR mutation independent manner. In addition, colony-forming assays were carried out to evaluate the long-term suppressive effects of AA treatment. After incubating with AA for 2 weeks, cell colonies were stained with crystal violet and counted. Results indicated that AA produced a strong inhibitory effect on the growth of NSCLC cells ( Figure 1C) .
AA induces NSCLC cell cycle arrest
To examine whether AA impacts NSCLC cell cycle distribution, the proportion of cells in G0/G1, S, and G2/M phases was counted by flow cytometry. The results indicated that AA effectively arrested PC-9 and H1975 cells at the G0/G1 phase (Figure 2A ). On the other hand, Western blot results suggested that AA dose-dependently downregulated the expression of G1/S transition regulatory proteins (cyclin D1 and cdk4, Figure 2B ). These results suggested that AA effectively arrested the cells in the G0/G1 phase through reducing the expression of cell cycle-related proteins.
AA treatment induces NSCLC cell apoptosis
Double-staining with annexin V-FITC and PI was performed to determine whether AA could exert the proapoptotic effect on NSCLC cells. Flow cytometry results indicated that compared with DMSO control group, earlyand late-stage apoptosis rates of PC-9 and H1975 cells were both greatly increased after treatment with AA for 24 hrs ( Figure 3A) .
To elucidate the mechanisms of AA-induced apoptosis, we examined the expression levels of the apoptosis-related proteins cleaved caspase-PARP and Bcl-2 by Western blot analysis. Figure 3B indicates the expression of proapoptotic molecules cleaved-PARP was significantly upregulated, while the anti-apoptotic protein bcl-2 was downregulated.
AA binds directly to IKKβ and suppresses the IKKβ/Nf-κB signaling pathway in NSCLC cells
The transcription factor NF-κB and its associated regulatory factors, the IKKs, are involved in the pathogenesis of a variety of hematologic and solid tumor malignancies (eg, NSCLC, gastric cancer, breast tumors, etc.). Previously, Thummuri et al showed that AA suppressed activation of The data were obtained from 3 independent experiments. (C) Effect of AA on PC-9 and H1975 cells clone formation. Cells were exposed to each group for 7 days. Visualized colonies were photographed. The data were obtained from three independent experiments performed in triplicate, and the representative photos were shown.
the RANKL-induced IKKβ-IκB-NF-κB signaling pathway in a dose-dependent manner. 28 Therefore, we speculated that the anti-lung cancer activity of AA may also be involved with inhibition of the IKKβ/NF-κB signaling pathway. TNF-α, a well-known NF-κB activator, was used to activate the IKKβ/NF-κB pathway. The phosphorylation and total protein expression levels of IKKβ and IκB were analyzed by Western blot. The results showed that AA dose-dependently decreased IKKβ and IκB phosphorylation levels following stimulation with TNF-α (10 ng/mL) for 0.5 and 1 hr, respectively ( Figure 4A ). As a transcription factor, NF-κB must translocate to the nucleus to regulate target gene transcription. Thus, we also measured the subcellular localization of NF-κB p65 after treatment with AA. The levels of NF-κB p65 subunit in the nuclear and cytosolic fractions were quantified by Western blot. As shown in Figure 4B , AA effectively blocked the nuclear translocation of NF-κB.
To investigate whether AA bound directly to IKKβ, SPR experiments were performed. As shown in Figure 4C , the SPR response value increased gradually with elevated AA concentrations and a low equilibrium dissociation constant (KD) of 32 μM was determined. Besides, to validate the specificity of binding capacity of AA to IKKβ, as well as rule out the artificial effects in our SPR assay, the interaction between AA and IKK α was also determined. The results ( Figure 4D ) demonstrated that the binding of AA to IKKα was much lower than IKK beta, suggesting AA might be a potential selective IKKβ inhibitor. Collectively, these results indicate that AA bound directly to IKKβ, preventing the phosphorylation of IKKβ and IκB, and the subsequent nuclear translocation of NF-κB.
To clarify the causal relationship between the functional effects and the signaling pathway, IKKβ expressing plasmid was transfected into PC-9 cells (PC-9/IKKβ) and the levels of p-IKKβ and total IKKβ expression were assessed. The results ( Figure 5A ) showed that IKKβ overexpression successfully increased the protein levels as well as the phosphorylation degree of IKKβ in cells. Consistently, using this overexpressed cell line, we found that overexpression of IKKβ severely impaired AA-induced anti-proliferative and apoptosis effects in PC-9 cells (Figure 5B and C) . These findings supported the role of IKKβ in AA-mediated cytotoxicity in NSCLC cells.
Analysis of the AA binding site by molecular modeling
Firstly, molecular docking was used to predict the possible interactions between IKKβ and AA. Next, 100 ns MD simulations were performed to analyze their dynamic behavior. The root-mean square deviations (RMSDs) of all the backbone atoms of IKKβ, and the heavy atoms of AA were analyzed to validate the stability of the IKKβ/AA complex. As shown in Figure 6A , the RMSD values of backbone atoms of IKKβ have a small fluctuation after 25 ns and AA exhibited relative stability during the whole simulation. These findings indicated that through MD simulations we had determined a relatively reasonable binding conformation for our IKKβ/AA complex.
An MD simulation trajectory of the last 20 ns was performed to determine the role of individual residues in protein-ligand recognition patterns. The binding free energies were decomposed into the contributions of each residue based on the MM/GBSA method. As shown in Figure  6B , the 10 highest contributing residues were Ile-371, Lys-310, Leu-376, His-380, Leu-123, Leu-311, Asn-308, Met-384, Val-312 and Leu-307 ( Figure 6B ). Structural analysis suggested that AA binds to the allosteric pocket of IKKβ to block its activation. The interactions were primarily hydrophobic ( Figure 6C ). Overall, combining the SPR results with the two simulation methods, we concluded that IKKβ may be the target of AA.
Discussion and conclusions
Despite the tremendous efforts and progress in the past decades, anti-cancer drug development has been considerably hampered by the limited source of chemical scaffolds. NPs consist of a rich source of compounds with abundant structural diversity, and have been extensively explored in the field of anti-cancer drug discovery. 29 As the largest class of NPs, terpenoids include approximately 25,000 chemical structures, and a growing number of terpenoids have exhibited anticancer activities. 30 Celastrol, triptolide and andrographolide are representative terpenoids with anti-cancer activity, and their potential molecular mechanisms are all involved to IKKβ/NF-κB signal pathway. AA was another promising natural-derived diterpenoids compound, which had been proved to possess significant anti-inflammatory and anti-obesity effect. Oral preparations of AA have been used in clinical studies to treat psoriasis in China, which support the basic safety features of AA in developing it as an anti-tumor agent. In a recent research, Hsieh et al showed that AA could exert inhibitory effects on the metastasis of melanoma cancer. 15 However, the anti-lung cancer effects of AA have yet to be investigated. In this study, the inhibitory effects AA against NSCLC cells were evaluated for the first time. Based on our results, AA significantly reduced the proliferation and growth of NSCLC cells, but showed no cytotoxicity against human pulmonary epithelial (Beas-2B) cells. Meanwhile, AA dose-dependently induced cell cycle arrest and apoptosis in NSCLC cells. Given these effects, we believe AA is an effective and low-toxic anti-NSCLC compound.
As a crucial regulator of survival, apoptosis and migration of cancer cells; the IKKβ/NF-κB signaling pathway has been linked to the oncogenic potential of various cancers. 31, 32 Three potent IKKβ inhibitors, TPCA-1, BMS345541 and ML-120B, were previously evaluated for their anti-cancer effects in preclinical research. 33 The chronic toxicity of ML-120B and TPCA-1 found in experiments, however, greatly restricts their further clinical application. In a previous study, Thummuri et al reported that AA alleviated RANKLinduced osteoclastogenesis and inflammation-associated osteolysis through suppressing NF-κB and MAPK signaling. 28 In our study, Western blot results suggested AA could also inhibit activation of the IKKβ/NF-κB pathway in NSCLC cells. SPR analysis further confirmed that AA is a direct and potential selective IKKβ inhibitor. Moreover, overexpression of IKKβ rescued the inhibitory effects of AA, implicating the functional effects of AA was highly IKKβ/NF-κB inhibition dependent ( Figure 7 ). Molecular docking and simulation analyses showed that IKKβ inhibition by AA mainly depends on hydrophobic interactions with the hydrophobic cavity of IKKβ. We noticed this result was highly consistent with the extremely hydrophobic structural characteristics of AA, which suggested that to enhance IKKβ inhibitory activity, a modification introducing more hydrogen donors should be performed. Furthermore, introducing a long-chain hydrophilic moiety in the aromatic ring oriented away from the allosteric pocket may effectively increase water solubility and stabilize the binding conformation between AA and IKKβ. This could greatly improve the current poor druggability of AA. In summary, our results indicate AA significantly inhibits proliferation, arrests the cell cycle and promotes apoptosis of NSCLC cells. Mechanistically, our results demonstrate that AA could directly and selectively bind to IKKβ, preventing the phosphorylation of IKKβ and of the downstream molecule IκB, and reduces the nuclear translocation of NF-κB p65. Moreover, the IKKβ overexpression experiment suggests the anti-NSCLC effects of AA may be mainly mediated by its IKKβ inhibition. Finally, molecular docking and molecular simulations of the AA/IKKβ complex revealed that stable binding between these two molecules depended on hydrophobic interactions. Our results suggest that AA could be a lead compound for the discovery of novel IKKβ inhibitors, as well as a promising drug candidate for the treatment of NSCLC. 
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